Patient Information Leaflet: Briviact 10 mg/ml Injectable and Infusion Solution
Brivaracetam
Read this leaflet carefully before you start using this medicine, because
it contains important information for you.
-This medicine has been prescribed for you only. Do not give it to others even if they have the same symptoms as you, as it may harm them.
1.What Briviact is and what it is used for
2.What you need to know before you start using Briviact
3.How to use Briviact
4.Possible side effects
5.Storage of Briviact
6.Contents of the pack and additional information
What is Briviact
Briviact contains the active ingredient brivaracetam. It belongs to a group of medicines called “antiepileptics”. These medicines are used for the treatment of epilepsy.
What is Briviact used for
Do not use Briviact
Warnings and precautions
Consult your doctor or pharmacist before starting to use Briviact:
Children
Do not administer Briviact to children under 2 years of age.
Use of Briviact with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Particularly, inform your doctor if you are taking any of the following medications, as you will need to adjust your Briviact dose:
:
Use of Briviact with alcohol
Do not use this medication with alcohol.
Pregnancy and breastfeeding
Women of childbearing age should discuss the use of contraceptives with their doctor.
If you are pregnant or breastfeeding, or think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Briviact is not recommended for use during pregnancy or breastfeeding, as the effects of Briviact on pregnancy and the fetus are unknown.
Do not breastfeed your baby while taking Briviact, as Briviact is excreted in breast milk.
Do not stop treatment without consulting your doctor first. Stopping treatment may increase the number of your seizures and harm the baby.
Driving and operating machinery
Briviact containssodium
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
You will use Briviact along with other medications to treat epilepsy.
Dose
Your doctor will calculate the correct daily dose for you. Take the daily dose in two equal doses, with an interval of approximately 12 hours.
Adolescents and children weighing 50 kg or more, and adults
Adolescents and children weighing between 20 kg and less than 50 kg
Children weighing between 10 kg and less than 20 kg
Patients with liver problems
If you have liver problems:
How to use Briviact
Briviact is administered by a doctor or nurse as an intravenous injection or infusion. This medication is injected slowly into your vein or administered as an infusion (drip) for 15 minutes.
Duration of Briviact treatment
If you use more Briviact than you should
If you think you have been given too much Briviact, consult your doctor immediately.
If you interrupt Briviact treatment
If you have any other questions about using this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people may experience them.
Very Frequent:may affect more than 1 in 10 patients.
Frequent:may affect up to 1 in 10 patients.
Infrequent:May affect up to 1 in 100 patients
Other Adverse Effects in Children
Frequent:may affect up to 1 in 10 patients
-restlessness and hyperactivity (psychomotor hyperactivity)
Reporting Adverse Effects
If you experienceany type of adverse effect, consult your doctor or pharmacist, even if it is apossibleadverse effect that does not appear in this prospectus.You can also report them directlythrough thenational notification systemincluded in theAppendix V.By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Briviact Composition
The active ingredient is brivaracetam.
The other components are: sodium acetate (trihydrate), glacial acetic acid, sodium chloride, and water for injection preparations.
Appearance of the product and packaging contents
Briviact 10 mg/ml injectable and infusion solution is a transparent, colorless, and sterile solution.
Briviact 10 mg/ml injectable and infusion solution, 5 ml vial is packaged in a cardboard box with 10 vials.
Marketing authorization holder and manufacturer
Marketing authorization holder
UCB Pharma, S.A., Allée de la Recherche 60, B-1070, Brussels, Belgium.
Manufacturer
UCB Pharma, S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium.
For more information about this medication, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien UCB Pharma SA/NV Tél/Tel: + 32 / (0)2 559 92 00 | Lietuva UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Suomija) | |
???????? ? ?? ?????????? ???? Te?.: + 359 (0) 2 962 30 49 | Luxembourg/Luxemburg UCB Pharma SA/NV Tél/Tel: + 32 / (0)2 559 92 00(Belgique/Belgien) | |
Ceská republika UCB s.r.o. Tel:+ 420221 773 411 | Magyarország UCB Magyarország Kft. Tel.: + 36-(1) 391 0060 | |
Danmark UCB Nordic A/S Tlf: + 45 / 32 46 24 00 | Malta Pharmasud Ltd. Tel: + 356 / 21 37 64 36 | |
Deutschland UCB Pharma GmbH Tel:+ 49 /(0) 2173 48 4848 | Nederland UCB Pharma B.V. Tel.: + 31 / (0)76-573 11 40 | |
Eesti UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Soome) | Norge UCB Nordic A/S Tlf: +47/67 16 5880 | |
Ελλ?δα UCBΑ.Ε. Τηλ: + 30 / 2109974000 | Österreich UCB Pharma GmbH Tel: + 43-(0)1 291 80 00 | |
España UCB Pharma, S.A. Tel: + 34 / 91 570 34 44 | Polska UCB Pharma Sp. z o.o./VEDIM Sp. z o.o. Tel: + 48 22 696 99 20 | |
France UCB Pharma S.A. Tél: + 33 / (0)1 47 29 44 35 | Portugal UCB Pharma (Produtos Farmacêuticos), Lda Tel: + 351 / 21 302 5300 | |
Hrvatska Medis Adria d.o.o. Tel: +385 (0) 1 230 34 46 | România UCB Pharma Romania S.R.L. Tel: + 40 21 300 29 04 | |
Ireland UCB (Pharma) Ireland Ltd. Tel: + 353 / (0)1-46 37 395 | Slovenija Medis, d.o.o. Tel: + 386 1 589 69 00 | |
Ísland Vistor hf. Simi: + 354 535 7000 | Slovenská republika UCB s.r.o.,organizacná zložka Tel: + 421 (0) 2 5920 2020 | |
Italia UCB Pharma S.p.A. Tel: + 39 / 02 300 791 | Suomi/Finland UCB Pharma Oy Finland Puh/Tel: + 358 9 2514 4221 | |
Κ?προς Lifepharma (Z.A.M.) Ltd Τηλ: + 357 22 05 63 00 | Sverige UCB Nordic A/S Tel: + 46 / (0) 40 29 49 00 | |
Latvija UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Somija) | United Kingdom(Northern Ireland) UCB (Pharma)IrelandLtd. Tel:+353 / (0)1-46 37 395 |
Last revision date of this leaflet:
Other sources of information
The detailed information about this medication is available on the European Medicines Agency website:http://www.ema.europa.eu
This information is intended solely for healthcare professionals:
Briviact injectable and infusion solution can be administered as a bolus injection or as an infusion:
Briviact can be diluted with the following solutions: sodium chloride 9 mg/ml (0.9%), glucose injection 50 mg/ml (5%), or lactated Ringer's solution.
Each vial of Briviact injectable and infusion solution should be used only once (single-use). Unused solution should be discarded (see section 3).
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.